WIM
BSCN

Waycross Investment Management’s Invesco BulletShares 2023 Corporate Bond ETF BSCN Stock Holding History

Waycross Investment Management’s Portfolio BSCN Stock Details BSCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-725,081
Closed -$15.4M – 52
2023
Q3 		$15.4M Sell
725,081
-33,017
-4% -$700K 17.71% 1
2023
Q2 		$16M Sell
758,098
-19,317
-2% -$408K 16.74% 1
2023
Q1 		$16.4M Sell
777,415
-6,257
-0.8% -$132K 16.4% 1
2022
Q4 		$16.4M Buy
+783,672
New +$16.4M 16.6% 1

Other funds holding BSCN

SRC
Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
PP
Pacifica Partners Surrey, Canada $332M AUM 59.28% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Waycross Investment Management's BSCN Position: Q4 2023 in Review

Waycross Investment Management sold out of Invesco BulletShares 2023 Corporate Bond ETF (BSCN) in Q4 2023, closing a stake of 725,081 shares — an estimated $15.4M sold.

Waycross Investment Management first reported a position in BSCN in Q4 2022 and held it in 4 quarters. The position peaked at $16.4M in Q4 2022. 3 funds tracked by Wall St. Rank hold BSCN as of Q4 2023.

  • Waycross Investment Management reported no remaining Invesco BulletShares 2023 Corporate Bond ETF position as of Q4 2023 after selling out during the quarter.
  • Waycross Investment Management sold 725,081 Invesco BulletShares 2023 Corporate Bond ETF shares in Q4 2023, an estimated $15.4M.
  • Waycross Investment Management first reported a position in Invesco BulletShares 2023 Corporate Bond ETF in Q4 2022 and held it in 4 quarters.
  • Waycross Investment Management's Invesco BulletShares 2023 Corporate Bond ETF position peaked at $16.4M in Q4 2022.
  • 3 funds tracked by Wall St. Rank held Invesco BulletShares 2023 Corporate Bond ETF as of Q4 2023.

Based on Waycross Investment Management's 13F filing for Q4 2023, filed 10 Jan 2024.